NeoGenomics, Inc. (NEO) vs Personalis, Inc. (PSNL)
NeoGenomics, Inc. and Personalis, Inc. are both Diagnostics & Research companies. NeoGenomics, Inc. is the larger, with a market value of $2.5B against $1.8B — 1.4× the size. NeoGenomics, Inc. grew revenue faster over the last twelve months: 11.2% against −13.3%. NeoGenomics, Inc. has the higher net margin (−6.77% vs −153.8%) and the higher return on invested capital (−4.20% vs −317.5%). Across the 18 metrics below, NeoGenomics, Inc. leads on 15 and Personalis, Inc. on 3.
Valuation
Profitability
| Metric | NEO | PSNL | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 43.92% | 12.69% | 50.89% |
| Operating margin | (8.93%) | (164.07%) | (8.57%) |
| Net margin | (6.77%) | (153.84%) | (6.37%) |
| Free cash flow margin | (0.69%) | (144.76%) | 0.00% |
| Return on equity | (6.33%) | (50.32%) | (2.92%) |
| Return on assets | (3.78%) | (37.55%) | (6.71%) |
| Return on invested capital | (4.20%) | (317.48%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack